ACEi and ARBS in Hypertension and Heart Failure (eBook, PDF)

Redaktion: Perrone Filardi, Pasquale

• Format: PDF

Produktbeschreibung

The renin angiotensin system is implicated in the progression of atherosclerotic disease as well as of left ventricular dysfunction. Angiotensin converting enzyme inhibitors and AT1 receptor antagonists have been proven to reduce morbidity and mortality in patients with left ventricular dysfunction or in those at high cardiovascular risk with preserved ventricular function. This book is intended to summarize evidences and provide a rationale for the appropriate use of RAS antagonists in cardiovascular diseases. It will be presented as highly practical information on this topic, written in a quick-access, no-nonsense format. The emphasis will be on a just-the-facts clinical approach, heavy on tabular material, light on dense prose. The involvement of the ISCP will ensure that the best quality contributors will be involved and establish a consistent approach to each topic in the series and this title is no exception. It will contain practical illustrations and is designed to improve understand and practical usage of cardiovascular drugs in specific clinical areas.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Springer International Publishing
• Seitenzahl: 150
• Erscheinungstermin: 16. Oktober 2014
• Englisch
• ISBN-13: 9783319097886
• Artikelnr.: 43785390

Autorenporträt

Pasquale Ferrone Filardi is an Associate Professor of Cardiology and head of the Cardiology School at the University of Naples, Italy.

Inhaltsangabe

Pathogenetic mechanisms of RAS involvement in cardiovascular diseases.- Antiotensin converting enzyme inhibitors and at1 antagonists for treatment of hypertension.- Renin angiotensin system antagonism in heart failure.- Impact of co-morbidities on RAS inhibitors choice in hypertensive and heart failure patients.- Target organ damage and RAS blockade.